Clarity Pharmaceuticals Co-PSMA Abstract Accepted for Oral Presentation at EAU Annual Congress 2026.
Clarity Pharmaceuticals (ASX: CU6) announces that its abstract on the Co-PSMA Investigator-Initiated Trial (IIT) has been accepted for oral presentation at the European Association of Urology (EAU) Annual Congress 2026 in London. The trial, led by Prof. Louise Emmett, evaluated the diagnostic performance of Clarity's 64Cu-SAR-bisPSMA versus the standard 68Ga-PSMA-11 in detecting prostate cancer recurrence after radical prostatectomy in patients with low PSA levels. The Phase II study showed that 64Cu-SAR-bisPSMA identified more lesions, offering superior detection compared to current imaging agents. Dr. Alan Taylor, Executive Chairperson, highlighted the promising clinical results and the growing evidence for 64Cu-SAR-bisPSMA’s ability to improve prostate cancer diagnosis. With two FDA Fast Track Designations and ongoing registrational trials, Clarity is poised to expand its presence in the rapidly growing PSMA PET imaging market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Clarity Pharmaceuticals Co-PSMA Abstract Accepted for Oral Presentation at EAU Annual Congress 2026.
Clarity Pharmaceuticals (ASX: CU6) announces that its abstract on the Co-PSMA Investigator-Initiated Trial (IIT) has been accepted for oral presentation at the European Association of Urology (EAU) Annual Congress 2026 in London. The trial, led by Prof. Louise Emmett, evaluated the diagnostic performance of Clarity's 64Cu-SAR-bisPSMA versus the standard 68Ga-PSMA-11 in detecting prostate cancer recurrence after radical prostatectomy in patients with low PSA levels. The Phase II study showed that 64Cu-SAR-bisPSMA identified more lesions, offering superior detection compared to current imaging agents. Dr. Alan Taylor, Executive Chairperson, highlighted the promising clinical results and the growing evidence for 64Cu-SAR-bisPSMA’s ability to improve prostate cancer diagnosis. With two FDA Fast Track Designations and ongoing registrational trials, Clarity is poised to expand its presence in the rapidly growing PSMA PET imaging market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au